Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study
Authors' conclusion
After adjusting for confounders including age, among breast cancer patients aged over 50 years, AI use was not associated with increased risk of fracture compared to non-users. Tamoxifen use was linked to reduced risk of fracture, but not in patients under 50.
Study context
- Population
- Newly diagnosed breast cancer patients, 2008–2016, Korea Central Cancer Registry and Korean National Health Insurance Service69.1% received endocrine therapy
- Participants
- 63,021 participants
- Exposure
- Tamoxifen or aromatase inhibitor (AI) users vs non-users, by age
- Outcome
- Incidence of fractures by site
Methodological detailsnationwide, multivariable Cox proportional hazard model
- Nationwide
- Multivariable Cox proportional hazard model
Main finding
As reported in the abstract
Any fractures, adjusted
Hazard ratio (95% CI)P value
Tamoxifenvs Non-userspatients over 50
0.75(0.62–0.89)
P < 0.001AIvs Non-userspatients under 50
1.54(1.07–2.93)
P = 0.019Observational data: associations, not effects.
Further findings
Osteoporotic fracture incidence rate per 1,000 person-years
- Overall
- 7.4
- Under 50
- 3.5
- Over 50
- 12.6
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study. Osteoporos Int. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →